---
document_datetime: 2023-09-21 17:18:24
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/protopy-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: protopy-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8554327
conversion_datetime: 2025-12-24 05:58:36.968281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## For procedures finalised before 01/10/2003, please refer to module 8A

## MAJOR CHANGES 1

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Opinion issued on   | longer Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028 | Update of Summary of Product Characteristics and Package Leaflet Update of section 5.2 of the SPC to include information on tacrolimus blood concentrations in infants from age of 5 months and to specify the approved strengths of tacrolimus ointment used in the pharmacokinetic studies in adults and children following the assessment of a post approval commitment. Amendment of section 5.3 to correct a mistake in the route of administration used in a reproduction toxicity study. | 22/03/2007          | no 03/05/2007                                   | SPC, PL                          | Further to the CHMP assessment of the pharmacokinetic study FG-506-06-32 which characterised the PK profile of 0.03% tacrolimus in paediatric patients aged 3-24 months, the MAHamended Section 5.2 of the SPC to reflect the information on the absorption in infants from age of 5 months, as requested by the CHMP. The MAHhas also amended Section 5.3 to correct a mistake with respect to the route of administration in the male reproductive toxicity study. The Package leaflet has been amended to include the two new Member States, Bulgaria and Romania, to the list of local representatives. The contact details for some local representatives have also been updated. |
| R/0027  | Medicinal Renewal of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                | product 21/09/2006  | 20/11/2006                                      | SPC, Labelling, PL               | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile of Protopy continues to be favourable.                                                                                                                                                                                                                                                                                                              |

1 Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments

## Protopy

Medicinal product no longer authorised Procedural steps taken and scientific information after the authorisation Changes made after 01/10/2003

2 SPC (Summary of Product Characteristics), Labelling, PL (Package Leaflet)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                  |                                                                                                                                                                                                                                                                                                                               |                    |                      |         | The CHMP was also of the opinion that the renewal can be granted with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EMEA/H/ A-18/662 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004 (corresponding to Article 18 of Council Regulation (ECC) No 2309/93 of 22 July 1993), the European Commission requested on 21 April 2005 the opinion of the CHMP on the benefit/risk profile of Protopy in view of the potential risk of malignancies. | 23/03/2006         | 12/06/2006           | SPC, PL | authorised Please refer to the Scientific Conclusions: Protopy EMEA/H/A-18/662                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0022          | Update of Summary of Product Characteristics and Package Leaflet The Marketing Authorisation Holder applied for an update of section 4.8 (Undesirable effects) of the Summary of Product Characteristics and section 4 of the Package Leaflet to include information on rosacea following the assessment of the 5th PSUR.     | 21/04/2005         | no longer 10/06/2005 | SPC     | Based on the assessment of the 5th Periodic Safety Update Report the Marketing Authorisation Holder applied to update section 4.8 of the Summary of Product Characteristics to state that the adverse reaction, rosacea, has been reported after marketing. This information has also been included in section 4 of the Package Leaflet.                                                                                                                                                                                                                                                 |
| II/0017          | Medicinal Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                        | product 03/06/2004 | 02/08/2004           | SPC     | This variation concerns an update of section 4.2 of the Summary of Product Characteristics to amend the wording of the current prescription restriction from \"Protopic should only be prescribed by dermatologists and physicians with extensive experience in the treatment of atopic dermatitis with immunomodulating therapy\" to \"Protopic should be prescribed by physicians with experience in the treatment of atopic dermatitis\". The list of local representatives has also been updated to include the local representatives in the Accession Countries in the package leaflet. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0016   | Update of Summary of Product Characteristics                               | 03/06/2004         | 02/08/2004        | SPC     | This variation concerns an update of section 5.2 (Pharmacokinetic properties) of the Summary of Product Characteristics to include further information on the distribution of tacrolimus ointment following topical application.                                                                                                                 |
|-----------|----------------------------------------------------------------------------|--------------------|-------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015   | Update of Summary of Product Characteristics and Package Leaflet           | 03/06/2004         | 02/08/2004        | SPC, PL | authorised The MAHapplied for changes to the Summary of Product Characteristics and the Package Leaflet following the switch from COSTART terminology to MedDRA. New terms included represented the higher specificity of the MedDRA terminology and the changes reflected the change in terminology rather than a change in the safety profile. |
| II/0014   | Update of Summary of Product Characteristics                               | 03/06/2004         | longer 02/08/2004 | SPC     | This variation concerns an update of section 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics to include the results of three active comparator clinical studies.                                                                                                                                                      |
| II/0013   | Update of Summary of Product Characteristics                               | product 03/06/2004 | no 02/08/2004     | SPC     | This variation concerns an update of section 4.4 (Special warnings and special precautions for use) of the Summary of Product Characteristics following long-term experience for up to 4 years with consequential changes to section 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics.                                 |
| II/0012   | Medicinal Update of Summary of Product Characteristics and Package Leaflet | 03/06/2004         | 02/08/2004        | SPC, PL | The Marketing Authorisation Holder applied for an update of section 4.2 (Posology) of the SPC and of section 3 (How to use Protopic) of the Package Leaflet in order to delete the 3- week restriction on treatment duration for 0.1% tacrolimus twice daily treatment.                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0011   | Update of or change(s) to the pharmaceutical documentation   | 26/02/2004   | 01/03/2004   | The MAHapplied for changes to the manufacturing method of the active substance.   |
|-----------|--------------------------------------------------------------|--------------|--------------|-----------------------------------------------------------------------------------|

## MINOR CHANGES 3

| No      | Scope                                                                                                                                                            | Product Information affected 2   | Date 4     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------|
| IA/0026 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                  |                                  | 24/02/2006 |
| IA/0025 | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                   | PL                               | 19/10/2005 |
| IA/0024 | longer 01_Change in the name and/or address of the marketing authorisation holder 05_Change in the name and/or address of a manufacturer of the finished product | SPC, Labelling, PL               | 09/09/2005 |
| IA/0023 | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                   |                                  | 19/07/2005 |
| IB/0021 | 10_Minor change in the manufacturing process of the active substance                                                                                             |                                  | 10/03/2005 |
| IA/0020 | 13_a_Change in test proc. for active substance - minor change                                                                                                    |                                  | 10/02/2005 |
| IA/0019 | 38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                      |                                  | 29/11/2004 |
| N/0018  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                 | Labelling, PL                    | 16/11/2004 |
| IA/0010 | 06_a_Change in ATC code: Medicinal products for human use                                                                                                        | SPC                              | 04/12/2003 |
| IA/0009 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                  |                                  | 26/11/2003 |
| IA/0008 | 13_a_Change in test proc. for active substance - minor change                                                                                                    |                                  | 26/11/2003 |

<!-- image -->

Medicinal product no longer authorised

4 Date of entry into force of the change